GH Research Announces Publication of Phase 2b Results for Depression Treatment GH001

GH Research PLC (Nasdaq: GHRS) announced the publication of Phase 2b clinical trial results for its lead candidate, GH001, in the prestigious journal JAMA Psychiatry. The study focuses on GH001 (Mebufotenin), a treatment designed for patients suffering from treatment-resistant depression (TRD). A significant new analysis revealed that the drug's efficacy remains consistent regardless of the number of prior treatment failures a patient has experienced. This finding suggests that GH001 could serve a broader range of patients within the TRD population, significantly enhancing its market potential. The peer-reviewed publication provides critical clinical validation for the company's therapeutic approach and its potential to change psychiatric practice. Investors view this development as a positive step toward the future regulatory and commercial success of GH Research.

Sources:globenewswire.comquiverquant.comstocktitan.netgurufocus.commarkets.businessinsider.comintellectia.ai